You are leaving Lundbeck.com/US

You have chosen to visit another Lundbeck website or a third-party website, which is provided as a service to you. Lundbeck does not control content on third-party websites and cannot make representations concerning the accuracy of information on every website you visit. Lundbeck is not responsible for the privacy policy of any third-party website. We encourage you to read the privacy policy of every website you visit.

Click here to proceed

Cancel

Partnering

Generating innovation through collaboration

The complexity of brain diseases requires a concerted effort. We are committed to advancing science, from innovations born in house or externally, to develop new and better treatment options. We partner with mission-similar stakeholders to accelerate our efforts because our success – our patient’s success – depends on it.

Who we are

Lundbeck is globally recognized as one of the leading companies within neurological and psychiatric disorders. 

 

Partnering with external specialists in their respective fields of brain disease is a cornerstone of our strategy, and we always strive to be the partner of choice. Lundbeck holds the knowledge, capabilities and financial stability to spur innovation, both through our internal laboratories and external partners.

 

We enter into partnerships recognizing that your business strengths are different and complementary to our own. This is why we customize each partnership to ensure value creation and to translate today’s know-how into tomorrow’s advancements in life-changing therapies.

Areas of interest

Our primary ambition is to find innovative projects and products that will advance neuroscience and develop novel and innovative treatments for patients. By combining our internal R&D capabilities with external alliances, we significantly broaden the opportunities to achieve our end goal. These include:

 

  • Discovery technology platforms
  • Enabling technologies, such as biomarkers and imaging
  • Digital platforms, such as wearables
  • Discovery projects
  • Pre-clinical projects
  • Early and mid-stage developments projects
  • Regional and global commercialized products

Successful partnerships, from early-stage science to commercialization, have been one of the main drivers in establishing Lundbeck’s current position in brain science. We actively seek access to external innovation, particularly where we see best-in-class opportunities to develop transformative medicines, and where we can leverage our own global drug development and commercial expertise to bring new medicines to patients.

 

Our partnerships are equally valued, whether small or large, which allows us to fine-tune each partnership according to specific needs and circumstances. Across our therapeutic, technological and research areas, we seek:

Current partnerships & alliance management

The treatments we have launched over the last 10 years demonstrate Lundbeck’s ability and commitment to establishing exceptional partnerships. Once we’ve entered into a partnership, our Strategic Alliance Management Team takes the lead on laying the foundation for a well-functioning relationship. Some of our longstanding valued partnerships include:

Our partners

Lundbeck collaborates with companies, academic institutions, individuals, and third parties from around the world:

23andMe

IBM Watson

University of Glasgow

Alzheimer's Disease Neuroimaging Initiative

The Michael J. Fox Foundation

PD-Mito UANT

PHAG

CERVEAU

Massachusetts Life Sciences Center

NYU

Critical Path Institute

Alzheimer's Association

Wellcome

Mindstrong

Radar-CNS

Imprind

Ubiquent

Piramal

Confo

ImmunoBrain

Otsuka

Takeda

Mochida Pharmaceutical Co., Ltd.

Teva

Merz

Ovation

Chelsea Therapeutics

Prexton

Abide Therapeutics

Alder Biopharmaceuticals

Explore partnering opportunities

More from Lundbeck